Select Language

LAG-3

LAG-3 Overview

English Name	Lymphocyte activation gene 3 protein	Approved Drugs	1
Drugs in Clinical Trials	31	Target Synonym	Lymphocyte activation gene 3 protein，LAG3，Lymphocyte Activating 3，Lymphocyte-Activation Gene 3，CD223 Antigen，Protein FDC，CD223，LAG-3，FDC，sLAG-3
Highest Development Stage	Approved

English Name	Lymphocyte activation gene 3 protein
Target Synonym	Lymphocyte activation gene 3 protein，LAG3，Lymphocyte Activating 3，Lymphocyte-Activation Gene 3，CD223 Antigen，Protein FDC，CD223，LAG-3，FDC，sLAG-3
Approved Drugs	1
Drugs in Clinical Trials	31
Highest Development Stage	Approved

LAG-3 Product List

Product Category
Protein (20)Cell (1)Antibody (1)
Product Status
Launched (22)
Species
Human (10)Rat (1)Mouse (5)Cynomolgus (5)Canine (1)
Tag
His Tag (7)Fc Tag (3)Mouse IgG Fc Tag (3)Mouse IgG Fc Tag & Avi Tag (1)Llama IgG Fc Tag (1)Fc Tag & Avi Tag (2)His Tag & Avi Tag (3)- (2)
Conjugate
Unconjugated (13)Biotin-labeled (7)- (1)PE Labeled (1)

Cat. No.	Species	Host	Product Description
HOT LA3-H5222	Human	HEK293	Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
HOT LA3-H5255	Human	HEK293	Human LAG3 / CD223 Protein, Fc Tag, low endotoxin (MALS verified)
HOT LA3-H82E9	Human	HEK293	Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
HOT LA3-H82F3	Human	HEK293	Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
HOT LA3-M52H5	Mouse	HEK293	Mouse LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H525c	Human	HEK293	Human LAG-3 / CD223 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
LA3-H52Aa	Human	HEK293	Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
LA3-H52H3	Human	HEK293	Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H82Fb	Human	HEK293	Biotinylated Human LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-HP2H4	Human	HEK293	PE-Labeled Human LAG-3 / CD223 Protein, His TagStar Staining

Total: 22

LAG-3 Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

LAG-3 Synonyms

LAG3,CD223,FDC

Project Cooperation

Project Name	Drug Type	Therapeutic Area	Indication	Stage	Rights Area
LAG-3 mAb	Monospecific antibody	Oncology/Cancer	Advanced solid tumor	Phase I	Global

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Relatlimab	ONO-4482; BMS-986016	Phase 3 Clinical	Bristol-Myers Squibb Company	Adenocarcinoma; Brain metastases; Brain Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Medullary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Glioblastoma; Gliosarcoma; Hematologic Neoplasms; Hodgkin Disease; Large intestine neoplasm; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male Urogenital Diseases; Melanoma; Microsatellite instability-high cancer; Multiple Myeloma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms; Uveal melanoma	Details
Fianlimab	REGN-3767	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details
Tebotelimab	PD-1 X LAG-3; MGD-013	Phase 3 Clinical	Macrogenics Inc	Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
Mavezelimab/Pembrolizumab	MK-4280A; MK-4820A	Phase 3 Clinical	Merck Sharp & Dohme Corp	Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours	Details
SHR-1802	SHR-1802	Phase 2 Clinical	Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd	Neoplasms; Solid tumours	Details
Tobemstomig	RO-7247669	Phase 2 Clinical	F. Hoffmann-La Roche Ltd	Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Liver Neoplasms; Melanoma; Solid tumours	Details
Alcestobart	LBL-007	Phase 2 Clinical	Leads Biolabs Inc	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
Negalstobart	IBI-110	Phase 2 Clinical		Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Neoplasms; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck	Details
Mavezelimab	MK-4280	Phase 2 Clinical	Merck Sharp & Dohme Corp	Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Small Cell Lung Carcinoma	Details
Ieramilimab	IMP-701; LAG-525	Phase 2 Clinical	Immutep	Esophageal adenocarcinoma; Lymphoma, Large B-Cell, Diffuse; Melanoma; Ovarian Neoplasms; Persistent Fetal Circulation Syndrome; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms	Details
Miptenalimab	BI-754111	Phase 2 Clinical	C.H. Boehringer Sohn Ag & Co. Kg	Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours	Details
AK-129	AK-129	Phase 2 Clinical		Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	Details
HLX-26	HLX-26	Phase 2 Clinical		Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lymphoma; Solid tumours	Details
GLS-012	GLS-012	Phase 2 Clinical	Harbin Gloria Pharmaceuticals Co Ltd	Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours	Details
EMB-02	EMB-02	Phase 2 Clinical	Shanghai Epimab Biotherapeutics, Inc	Solid tumours	Details
DNV-3	DNV-3; DNV3	Phase 2 Clinical	Zhejiang Shimai Pharmaceutical Co Ltd	Lymphoma; Melanoma; Neoplasms; Skin Neoplasms; Solid tumours	Details
KL-A289	KL-A289	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Solid tumours	Details
Bavunalimab	XmAb-22841; XmAb-841	Phase 1 Clinical	Xencor Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Penile Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details
IMP-761	IMP-761	Phase 1 Clinical	Immutep	Autoimmune Diseases	Details
Sym-022	Sym-022; Sym022; S95017	Phase 1 Clinical	Symphogen A/S	Lymphoma; Neoplasm Metastasis; Solid tumours	Details
MIL-98	MIL-98	Phase 1 Clinical	Beijing Mabworks Biotech Co Ltd	Breast Neoplasms; Lymphoma; Melanoma; Solid tumours	Details
AN-8025	AN-8025	Phase 1 Clinical	Hangzhou Adlai Nortye Biopharma Co Ltd	Solid tumours	Details
ABL-501	ABL-501	Phase 1 Clinical	Abl Bio Inc	Solid tumours	Details
TQB-2252	TQB-2252; TQB2252	Phase 1 Clinical	Chia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd	Neoplasms; Solid tumours	Details
AK-137	AK137; AK-137	Phase 1 Clinical		Neoplasms	Details
SSGJ-709	SSGJ-709; SSGJ709	Phase 1 Clinical	Shenyang Sunshine Pharmaceutical Co Ltd	Neoplasms; Solid tumours	Details
JY-03	JY03; JY-03	Phase 1 Clinical	Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd	Solid tumours	Details
ZGGS-15	ZGGS15; ZGGS-15	Phase 1 Clinical	Suzhou Zelgen Biopharmaceuticals Co Ltd	Solid tumours	Details
IBI-323(Innovent Biologics)	IBI-323	Phase 1 Clinical		Neoplasms; Solid tumours	Details
Encelimab	TSR-033; TSR 033; TSR033; GSK-4074386	Phase 1 Clinical	Anaptysbio Inc	Neoplasms	Details
68Ga-DOTA-hLAG-3		Clinical	The First Affiliated Hospital Of Xiamen University	Neoplasms	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Nivolumab/Relatlimab	BMS-986213; BMS-936558/BMS-986016	Approved	Bristol-Myers Squibb Company	OPDUALAG	United States	Melanoma	Bristol-Myers Squibb Company	2022-03-18	Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Skin Melanoma; Solid tumours; Stomach Neoplasms	Details

Product Reviews

N***r2022-11-08
0People Like
Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
Ordered this reagent for a binding ELISA performed for a client. Client had questions about extending the reagent expiry and getting extra documentation provided for a GMP project. Acros customer service was great in answering all of my questions and providing documentation within just a few mins. I was provided with the COA and a memo ensuring the expiry could be extended from data that Acros had collected. I was also able to talk to other scientists on the technical side of their customer services and ensure that what I was relaying to the client was accurate. Really helped out on this project and the client was very happy! Thank you Acros!
1***12019-11-07
1People Like
Human LAG-3 / CD223 Protein, His Tag, low endotoxin (MALS verified)
I purchased Acro's protein many times for experiments. LAG3 was used mostly, and the titer after immunization can reach more than 100,000. It is a very good product.
1***92019-10-11
0People Like
Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
We purchased ACRO's Human LAG3-mFc protein, and we tested its affinity with the antibody on Biacore T200. The results showed that the affinity was within the normal range, and the protein bioactivity is very good!